Protalix BioTherapeutics, Inc.
PLXProtalix BioTherapeutics is a commercial-stage biopharmaceutical company specializing in the development and production of recombinant therapeutic proteins for rare and orphan diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Protalix BioTherapeutics is a commercial-stage biopharmaceutical company specializing in the development and production of recombinant therapeutic proteins for rare and orphan diseases. The company utilizes its proprietary ProCellEx platform, the first plant cell-based protein expression system to receive FDA approval, to create innovative treatments for indications with high unmet medical needs.
Protalix is a pioneer in plant cell-based protein expression, holding a unique regulatory position as the first company to commercialize a plant-cell derived recombinant protein approved by the FDA.
Questions, answered.
- What is Protalix BioTherapeutics, Inc.'s market cap?
- Protalix BioTherapeutics, Inc. (PLX) has a market capitalization of $191.0M and trades on AMEX.
- Who are Protalix BioTherapeutics, Inc.'s competitors?
- Protalix BioTherapeutics, Inc.'s key competitors include Sanofi, Takeda Pharmaceutical Company, REGENXBIO Inc., and others. These companies compete in similar markets and product categories.
- Who does Protalix BioTherapeutics, Inc. partner with?
- Protalix BioTherapeutics, Inc.'s notable partners include Pfizer Inc., Chiesi Farmaceutici S.p.A., Fundação Oswaldo Cruz (Fiocruz).
- What subsidiaries does Protalix BioTherapeutics, Inc. have?
- Protalix BioTherapeutics, Inc.'s subsidiaries include Protalix Ltd..
- Where is Protalix BioTherapeutics, Inc. headquartered?
- Protalix BioTherapeutics, Inc. is headquartered in United States of America and employs approximately 208 people. It has been publicly traded since 1996.